reference/25724253

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25724253

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	570
issn	1875-8908 1387-2877
issueIdentifier	2
pageRange	555-570
publicationName	Journal of Alzheimer's disease : JAD
startingPage	555
bibliographicCitation	Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease. J Alzheimers Dis. 2019;67(2):555–70. PMID: 30530975; PMCID: PMC6398557.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6af634e32f9defb283f08c4c525876bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_295b900fe55740805cb587aee82b7125 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79fe6c8f300bcc3d570d1475fad12883 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df74c861f4defe3136673212c1c68999 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eaa038169795d04a52deedd75df18fca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ada75ffbfb36fd9d0d5415ef1747914f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e204fe0351ef6cb51e03c09d4662fcba http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a93515fb660cea186fbb1b5e30358a30 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7a4ac3e9ddbaad054fb915e44797c51
date	2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC6398557 https://pubmed.ncbi.nlm.nih.gov/30530975 https://doi.org/10.3233/jad-180759
isPartOf	https://portal.issn.org/resource/ISSN/1875-8908 https://portal.issn.org/resource/ISSN/1387-2877 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
discusses	http://id.nlm.nih.gov/mesh/M0507120
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D054713Q000627 http://id.nlm.nih.gov/mesh/D000544Q000188 http://id.nlm.nih.gov/mesh/D054713Q000009
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D003071 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000203 http://id.nlm.nih.gov/mesh/D000544Q000523 http://id.nlm.nih.gov/mesh/D000073216 http://id.nlm.nih.gov/mesh/D007262 http://id.nlm.nih.gov/mesh/D010352 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000076723 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D054713Q000008 http://id.nlm.nih.gov/mesh/D004305
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID138319197 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280757 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID101348456 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4054 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25235992 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6435419

Total number of triples: 57.